Intima Bioscience has conducted a clinical trial at the University of Minnesota Masonic Cancer Center.
Please watch the video below to learn more about our proprietary CISH checkpoint.
Data from
First-in-Human Trial
targeting CISH
First-in-Human Trial
targeting CISH
a Novel Immune Checkpoint,
in Patients with Metastatic
Colorectal Cancer
in Patients with Metastatic
Colorectal Cancer
Presented at 2025 American
Association for Cancer Research (AACR)
Annual Meeting
Association for Cancer Research (AACR)
Annual Meeting
A clinical-stage company focused on a
next-generation small molecule checkpoint inhibitor
next-generation small molecule checkpoint inhibitor
CISH IMMUNE CHECKPOINT TARGET
THE NEXT GENERATION OF
CANCER PLATFORM TECHNOLOGY
CISH: a novel immune
checkpoint
checkpoint
Small molecule
checkpoint inhibitor
checkpoint inhibitor
DRUGGING
THE UNDRUGGABLE
INTIMA BIOSCIENCE CLINICAL TRIAL
A clinical trial employing CRISPR genetically engineered CISH-knockout T-cells as a model system to evaluate the safety and efficacy of this classically undruggable intracellular target.
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
NEWS
Data from First-in-Human Trial targeting CISH, a Novel Immune Checkpoint, in Patients with Metastatic Colorectal Cancer
PUBLICATIONS
Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer (Lancet Oncology)
CISH, a novel intracellular immune checkpoint, in comparison and combination to existing and emerging cancer immune checkpoints
First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint CISH is inhibited
Presented at the American Association for Cancer Research (AACR),April 25-30, 2025, Chicago, IL
Presented at the American Association for Cancer Research (AACR),
Homology mediated end joining enables efficient non-viral targeted integration of large DNA templates in primary human T cells
Genetic editing of CISH enhances T cell effector programs independently of immune checkpoint cell surface ligand expression
Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
A Bioinformatic and Empiric Exploration of Prokaryotic Argonautes as Novel Programmable Endonuclease Systems
A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL)
AAV Capsid Chimeras with Enhanced Infectivity reveal a core element in the AAV Genome critical for both Cell Transduction and Capsid Assembly
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade
TECHNOLOGY PLATFORM
T Cells
CISH Checkpoint Target
Small molecule inhibitor
Cutting-edge Small Molecule
Intra-cellular protein-protein strategies to drug the undruggable
Next Generation Checkpoint
CISH is a novel intra-cellular immune checkpoint and an important negative regulator of T-cell signaling and function
New York City | Cambridge UK
Intima Bioscience, Inc.
3 Columbus Circle, New York, NY 10019, USA
Building 250, Babraham Research Campus, Cambridge, CB22 3AT, UK
